AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02870543
Drug: Phytolacca decandra
RxNorm normalized name: Phytolacca Decandra 6X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of bruxism
Trial: NCT02870543
Drug: Melissa officinalis
RxNorm normalized name: melissa officinalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of bruxism
Trial: NCT02870543
Drug: Phyt.decandra + Melissa offic.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of bruxism
Trial: NCT02171455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00075231
Drug: Combivir® (lamivudine, zidovudine)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00075231
Drug: Sustiva® (efavirenz)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01919710
Drug: rHSA/GCSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for treatment of neutropenia
Trial: NCT00447759
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200-400mg daily in divided doses
Trial: NCT00447759
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: prescribed medication taken orally
Trial: NCT02765165
Drug: USL311
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once weekly in a 21-day cycle
Trial: NCT02765165
Drug: USL311
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once daily in a 21-day cycle
Trial: NCT02765165
Drug: USL311
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once daily in a 42-day cycle
Trial: NCT00505921
Drug: Campath-1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg through the catheter Day 1 then 10 mg on Day 2, and 30 mg on Days 3 and 10 of chemotherapy treatment.
Trial: NCT01493648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo (lactose 100 mg) for 3 months.
Trial: NCT00505921
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4).
Trial: NCT00772837
Drug: Omeprazole + Clarithromycin + Amoxycillin
RxNorm normalized name: clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BD and Amoxycillin 1g BD for 1 week
Trial: NCT00079742
Drug: Nutropin AQ [somatropin (DNA origin) injection]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04579965
Drug: medical treatment of isthmocele
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison between different drugs
Trial: NCT00141609
Drug: Slow Sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00025402
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04342169
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to be taken on the same schedule as HCQ.
Trial: NCT01349725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral; matching placebo
Trial: NCT02456896
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After baseline assessments, patients in test group will be prescribed Tab. Oxcarbazepine (600mg/daily in two divided dose for 1 week followed by 900mg/daily in two divided dose for next 3 weeks).
Trial: NCT00157053
Drug: Antihemophilic factor, recombinant, manufactured protein-free
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02860923
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00660374
Drug: EX1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft-treat-to-target dose titration scheme, injection s.c.
Trial: NCT03937687
Drug: Caffeine+TeaCrine+Dynamine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: combination of caffeine, TeaCrine, and Dynamine
Trial: NCT03937687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03937687
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine
Trial: NCT00991276
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules; 0 mg once-per-day; 4 weeks of treatment
Trial: NCT03813056
Drug: Optive, Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: artificial tears (placebo)
Trial: NCT05163756
Drug: DW1903
FDA approved: no
EMA approved: no
PMDA approved: no
Description: q.d. PO, DW1903 + Placebo of DW1903-R1
Trial: NCT00287339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule BID for 12 weeks
Trial: NCT02774252
Drug: BAY987521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation number - Y49-103)
Trial: NCT04598204
Drug: Treatment with oral rapmycin
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To treat the enrolled patients with oral rapamycin with an initial dosage of 0.8mg/m2, once daily for children under 3 years old and twice daily (every 12 hours) for those above 3 years, and adjust the dosage to target a trough concentration of rapamycin in plasma as 10-15ng/ml （OR 15-20ng/ml if the efficacy of treatment is not satisfactory）. One course lasts for 12weeks and no more than 4 course is given.
Trial: NCT00544362
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02240693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01386281
Drug: E2 transdermal (Julina, BAY86-5435)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
Trial: NCT01211522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.
Trial: NCT02411643
Drug: topical calcipotriene 0.005% ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Affected area will be treated twice daily for 3 months
Trial: NCT03282929
Drug: Part 2 group 2
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
Trial: NCT03393520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsules
Trial: NCT00630344
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00249483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00657774
Drug: FlutiForm 250/10 ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
Trial: NCT00657774
Drug: FlutiForm 100/10 ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKP FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
Trial: NCT00657774
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 5 mg placebo tablets, over encapsulated, once a day for six weeks. SKP FlutiForm placebo HFA pMDI. Two actuations BID for six weeks.
Trial: NCT01743651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day
Trial: NCT01579149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous (SC) dose of placebo
Trial: NCT02742051
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant chemotherapy
Trial: NCT02742051
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant chemotherapy
Trial: NCT03124108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two coated tablets daily for 12 weeks
Trial: NCT01570205
Drug: XG-102
RxNorm normalized name: Ninjacof XG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intravenous infusion
Trial: NCT01839253
Drug: ACE inhibitor(Enapril)
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02224937
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02224937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01769482
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03432572
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: active placebo not known to cause urine discoloration
Trial: NCT00288236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02370043
Drug: KQ-791
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally while fasting, in up to 3 periods
Trial: NCT02370043
Drug: KQ-791 (after meal)
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of KQ-791 in capsules, after a meal, in 1 period
Trial: NCT02370043
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, administered orally, in 1 period
Trial: NCT02035124
Drug: BKM 120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04723186
Drug: MT1002 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT1002 will be initiated as close to the start of PCI as possible. MT1002 should be initiated during diagnostics angiography when indication for PCI is confirmed, provided the PCI is indicated right after the coronary angiography. PCI can start after MT1002 initiation as soon as ACT is confirmed to be ≥ 200 sec or within 30 min after MT1002 starts, whichever occurs first. MT1002 will be administered by an intravenous injection of 0.90 mg/kg, 1.2 mg/kg, or 0.6 mg/kg (depending on the dose selected for the cohort) prior to the PCI procedure, immediately followed by an IV infusion of 1.8 mg/kg/hour, 2.3 mg/kg/hour, or 1.2 mg/kg/hour (depending on the dose selected for the cohort) until completion of the procedure. At completion of PCI, subjects will be continued on IV MT1002 for 4 hours from infusion start.
Trial: NCT02105350
Drug: MEK 162
RxNorm normalized name: Mitogen-activated protein kinase (MEK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03480971
Drug: Placebo Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo contains the same excipients as the active product plus FD\&C Yellow #6 for color matching.
Trial: NCT03168438
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
Trial: NCT04427501
Drug: LY3819253
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT00769418
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: placebo to odanacatib tablets 2.5 mg qd for 14 days.~Panel B: placebo to odanacatib tablets 5 mg qd for 14 days.~Panel C: placebo to odanacatib tablets 10 mg qd for 14 days.~Panel D: placebo to odanacatib tablets 25 mg qd for 14 days.~Panel E: placebo to odanacatib tablets 0.5 mg qd for 21 days.~Panel F: placebo to odanacatib tablets 2.5 mg qd for 21 days.~Panel G: placebo to odanacatib tablets 10 mg qd for 21 days.
Trial: NCT04427501
Drug: LY3853113
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT00806728
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of normal saline on Days 16, 23, 30, and 37.
Trial: NCT00806728
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of MEDI-507 on Days 16, 23, 30, and 37.
Trial: NCT01359943
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to AIN457 i.v. and to AIN457 s.c..
Trial: NCT04427501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT01898039
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered.
Trial: NCT03124082
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuous infusion intraop
Trial: NCT04530344
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Trial: NCT00172107
Drug: ALX1-11 50 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH(1-84) 50 mcg for subcutaneous injection into thigh or abdomen
Trial: NCT00172107
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo powder for subcutaneous injection
Trial: NCT00172107
Drug: ALX1-11 75mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH(1-84)75 mcg for subcutaneous injection
Trial: NCT00172107
Drug: ALX1-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH (1-84) 100mcg for subcutaneous injection into thigh or abdomen
Trial: NCT00026208
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 650 mg/m², on week 1 and 5
Trial: NCT00026208
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m², on week 1, 3, 5, 7
Trial: NCT00352183
Drug: Fenofibrate/Simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Fenofibrate and Simvastatin 40mg
Trial: NCT00352183
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40mg
Trial: NCT00546507
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01553851
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib (GSK1120212) is a selective MEK1 and MEK2 inhibitor with selective activity towards BRAF and RAS mutant cancer cell lines and hematopoietic cancer cells from AML and CML origins.
Trial: NCT00205166
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine 400 mg po
Trial: NCT00205166
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine 200 mg po
Trial: NCT04338529
Drug: Binosto 70Mg Effervescent Tablet
RxNorm normalized name: Binosto 70mg Effervescent Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As discussed in group descriptions
Trial: NCT01723774
Drug: PD0332991
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02939183
Drug: Immediate Release (IR) Formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Release (IR) Formulation
Trial: NCT02939183
Drug: Gastro-Retentive (GR) Formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastro-Retentive (GR) Formulation
Trial: NCT03416179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (PO) given on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, placebo will be administered daily for up to 2 years after randomization or until they have MRD negative disease, whichever comes first.~Daily placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.
Trial: NCT03416179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (PO) is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue placebo until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
Trial: NCT00484510
Drug: Ascorbic acid (Vitamin C)
RxNorm normalized name: Ascorbic acid (vitamin C), plain
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight 500 mg capsules/day of ascorbic acid. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months. (Total 4 gr/day).
Trial: NCT01711125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3 matched tabs/day
Trial: NCT00484510
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eight 500 mg capsules/day of placebo. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months.
Trial: NCT02749331
Drug: AdVince
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virus solution for infusion in intrahepatic artery
Trial: NCT01299584
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basically there is no treatment allocation. Subjects who would be administered of remifentanil at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Trial: NCT01465815
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01364220
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 20mg tablet, once daily, for 14 days
Trial: NCT02682121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily
Trial: NCT02424695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03057418
Drug: Aurixim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration will be performed once a week during 4-week induction period, and then once per 12 weeks during supporting period, if necessary. Total maximum duration of the investigational therapy - 1 year, during which patients will receive up to 8 infusions of Aurixim.
Trial: NCT00300729
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
Trial: NCT00300729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
Trial: NCT00568503
Drug: QAX028
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00568503
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06108921
Drug: Salt Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The bilateral nasal cavity was irrigated by using a Sanvic SH903 pulsatile irrigator containing 400 ml of normal saline once a day for 2 months.
Trial: NCT04423731
Drug: Folfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy is given according to different regimens, preferably FOLFIRINOX according to the recommendations in the national Norwegian guidelines. The choice of chemotherapy regimen is decided by the treating oncologist.
Trial: NCT04083183
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01573143
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin (20 mg od) started not earlier than 8 days before surgery and continued until the 5th post-operative day included;
Trial: NCT01573143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo started not earlier than 8 days before surgery and continued until the 5th post-operative day included.